Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 297 articles:
HTML format



Single Articles


    September 2021
  1. MONTORSI F, Moschini M, Necchi A, Deho F, et al
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Letter.
    J Urol. 2021 Sep 14:101097JU0000000000002237. doi: 10.1097/JU.0000000000002237.
    PubMed    


  2. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Response.
    J Urol. 2021 Sep 14:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  3. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Implications for Clinical Trial Design. Reply.
    J Urol. 2021 Sep 2:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  4. SHARMA V, Miest TS, Juvet TS, Toussi A, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis.
    J Urol. 2021;206:558-567.
    PubMed     Abstract available


  5. PETROS FG, Choi W, Qi Y, Moss T, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2021;206:548-557.
    PubMed     Abstract available


  6. KATIMS AB, Say R, Derweesh I, Uzzo R, et al
    Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).
    J Urol. 2021;206:568-576.
    PubMed     Abstract available


    August 2021
  7. D'ANDREA D, Black PC, Zargar H, Dinney CP, et al
    Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2021 Aug 27:101097JU0000000000002190. doi: 10.1097/JU.0000000000002190.
    PubMed     Abstract available


  8. PATEL HD, Patel SH, Blanco-Martinez E, Kuzbel J, et al
    Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival.
    J Urol. 2021 Aug 27:101097JU0000000000002189. doi: 10.1097/JU.0000000000002189.
    PubMed     Abstract available


  9. CHEVLI KK, Shore ND, Trainer A, Smith AB, et al
    Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    J Urol. 2021 Aug 26:101097JU0000000000002186. doi: 10.1097/JU.0000000000002186.
    PubMed     Abstract available


  10. MERSEBURGER AS, Castellano D, Powles T, Loriot Y, et al
    Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
    J Urol. 2021;206:240-251.
    PubMed     Abstract available


  11. PATEL SR, Lerner SP
    Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma.
    J Urol. 2021;206:191-193.
    PubMed    


    July 2021
  12. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.
    PubMed    


  13. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    PubMed     Abstract available


    June 2021
  14. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    PubMed     Abstract available


    May 2021
  15. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    J Urol. 2021 May 25:101097JU0000000000001855. doi: 10.1097/JU.0000000000001855.
    PubMed     Abstract available


  16. MARTINI A, Afferi L, Zamboni S, Schultz JG, et al
    Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy.
    J Urol. 2021 May 25:101097JU0000000000001886. doi: 10.1097/JU.0000000000001886.
    PubMed     Abstract available


  17. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    PubMed     Abstract available


  18. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    PubMed     Abstract available


  19. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed     Abstract available


  20. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    PubMed     Abstract available


    April 2021
  21. BREE KK, Hensley PJ, Westerman MB, Kokorovic A, et al
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.
    J Urol. 2021 Apr 19:101097JU0000000000001784. doi: 10.1097/JU.0000000000001784.
    PubMed     Abstract available


  22. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Reply by Authors.
    J Urol. 2021;205:998.
    PubMed    


  23. SOUNTOULIDES P, Pyrgidis N, Brookman-May S, Mykoniatis I, et al
    Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
    J Urol. 2021;205:956-966.
    PubMed     Abstract available


  24. SHVERO A, Abu-Ghanem Y, Laufer M, Dotan ZA, et al
    Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:1039-1046.
    PubMed     Abstract available


    March 2021
  25. LUSTY A, Doiron RC, Booth CM, Whitehead M, et al
    No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.
    J Urol. 2021 Mar 30:101097JU0000000000001715. doi: 10.1097/JU.0000000000001715.
    PubMed     Abstract available


  26. YANAGISAWA T, Miki J, Sakanaka K, Fukuokaya W, et al
    Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001735. doi: 10.1097/JU.0000000000001735.
    PubMed     Abstract available



  27. Erratum: Perceptions of Link between Smoking and Bladder Cancer among United States Adults.
    J Urol. 2021;205:942.
    PubMed    



  28. Erratum: Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
    J Urol. 2021;205:942.
    PubMed    


  29. DAS A, Cohen JE, Ko OS, Jordan BJ, et al
    Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    J Urol. 2021;205:693-700.
    PubMed     Abstract available


  30. TAGUCHI S, Tambo M, Watanabe M, Machida H, et al
    Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful?
    J Urol. 2021;205:686-692.
    PubMed     Abstract available


  31. SWAMI U, Haaland B, Kessel A, Nussenzveig R, et al
    Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    J Urol. 2021;205:709-717.
    PubMed     Abstract available


    February 2021
  32. BHAT A, Kwon D, Soodana-Prakash N, Mouzannar A, et al
    Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
    J Urol. 2021 Feb 22:101097JU0000000000001689. doi: 10.1097/JU.0000000000001689.
    PubMed     Abstract available


  33. ZHU D, Srivastava A, Agalliu I, Fram E, et al
    Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
    J Urol. 2021 Feb 22:101097JU0000000000001694. doi: 10.1097/JU.0000000000001694.
    PubMed     Abstract available


  34. MICHELLE R, Liguori G, Trombetta C
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis. Letter.
    J Urol. 2021 Feb 12:101097JU0000000000001649. doi: 10.1097/JU.0000000000001649.
    PubMed    


  35. ZIBELMAN M, Asghar AM, Parker DC, O'Neill J, et al
    Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
    J Urol. 2021 Feb 4:101097JU0000000000001602. doi: 10.1097/JU.0000000000001602.
    PubMed     Abstract available


  36. FURRER MA, Kiss B, Studer UE, Wuethrich PY, et al
    Seminal Vesical Sparing Cystectomy in Bladder Cancer Patients is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
    J Urol. 2021 Feb 3:101097JU0000000000001635. doi: 10.1097/JU.0000000000001635.
    PubMed     Abstract available


  37. GHOREIFI A, Djaladat H
    Re: Intra-Operative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication RatesDonat SM, Tan KS, Jibara G, Dalbagni G, Arslan Carlon V, Sandhu J J Urol 2020; doi:10.1097/JU.0000000000001329.
    J Urol. 2021;205:335-336.
    PubMed    


  38. DONAT SM, Tan KS, Jibara G, Dalbagni G, et al
    Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates.
    J Urol. 2021;205:483-490.
    PubMed     Abstract available


  39. CACCIAMANI GE, Medina L, Lin-Brande M, Tafuri A, et al
    Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.
    J Urol. 2021;205:491-499.
    PubMed     Abstract available


  40. ELSAYED AS, Gibson S, Jing Z, Wijburg C, et al
    Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2021;205:407-413.
    PubMed     Abstract available


  41. GALLIOLI A, Territo A, Mercade A, Fontana M, et al
    The Impact of Ureteroscopy following Computerized Tomography Urography in the Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:392-399.
    PubMed     Abstract available


  42. WEI XX, Werner L, Teo MY, Rosenberg JE, et al
    Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    J Urol. 2021;205:414-419.
    PubMed     Abstract available


  43. CHESNUT GT, Tin AL, Sjoberg DD, Jang B, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy.
    J Urol. 2021;205:400-406.
    PubMed     Abstract available


    January 2021
  44. MATULAY JT, Li R, Hensley PJ, Brooks NA, et al
    Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
    J Urol. 2021 Jan 27:101097JU0000000000001633. doi: 10.1097/JU.0000000000001633.
    PubMed     Abstract available


  45. YANAGISAWA T, Miki J, Yorozu T, Iwatani K, et al
    Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    J Urol. 2021 Jan 27:101097JU0000000000001630. doi: 10.1097/JU.0000000000001630.
    PubMed     Abstract available


  46. WEIN AJ
    Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology.
    J Urol. 2021;205:309-312.
    PubMed    


  47. MEEKS JJ
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  48. HATAKEYAMA S, Hamano I, Ohyama C
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  49. HAUTMANN RE, Volkmer B, Egghart G, Frohneberg D, et al
    Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center.
    J Urol. 2021;205:174-182.
    PubMed     Abstract available


    December 2020
  50. PETRUZELLA S, Bochner BH, Kenney J, Whiting K, et al
    Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.
    J Urol. 2020 Dec 24:101097JU0000000000001571. doi: 10.1097/JU.0000000000001571.
    PubMed     Abstract available


  51. KIRSCHNER AN, Wang J, Rajkumar-Calkins A, Neuzil KE, et al
    Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
    J Urol. 2020 Dec 24:101097JU0000000000001576. doi: 10.1097/JU.0000000000001576.
    PubMed     Abstract available


  52. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis.
    J Urol. 2020 Dec 7:101097JU0000000000001513. doi: 10.1097/JU.0000000000001513.
    PubMed     Abstract available


  53. CHANG SS
    Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?
    J Urol. 2020;204:1378.
    PubMed    


  54. MORI K, Abufaraj M, Mostafaei H, Quhal F, et al
    A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
    J Urol. 2020;204:1129-1140.
    PubMed     Abstract available


    November 2020
  55. DE JONG FC, Hoedemaeker RF, Kvikstad V, Mensink JTM, et al
    T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.
    J Urol. 2020 Nov 16:101097JU0000000000001422. doi: 10.1097/JU.0000000000001422.
    PubMed     Abstract available


  56. YIN G, Tang J, Wang L
    Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boeve, E. H. G. M. Oomens, N. J. van Casteren, M. Krispi
    J Urol. 2020;204:1062.
    PubMed    


  57. HANNA PT, Peterson M, Albersheim J, Drawz P, et al
    Acute Kidney Injury following Enhanced Recovery after Surgery in Patients Undergoing Radical Cystectomy.
    J Urol. 2020;204:982-988.
    PubMed     Abstract available


  58. WANG DS
    Re: Epidural Anesthesia is Associated with Increased Complications in Cystectomy Patients: A NSQIP Analysis.
    J Urol. 2020;204:1072-1073.
    PubMed    


    October 2020
  59. MYRIE AK, Matulewicz RS
    Perceptions of the Link Between Smoking and Bladder Cancer Among United States Adults.
    J Urol. 2020 Oct 14:101097JU0000000000001415. doi: 10.1097/JU.0000000000001415.
    PubMed    


  60. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    PubMed     Abstract available


  61. ALMASSI N, Cha EK, Vertosick EA, Huang C, et al
    Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.
    J Urol. 2020;204:677-684.
    PubMed     Abstract available


  62. CACCIAMANI GE, Ghodoussipour S, Mari A, Gill KS, et al
    Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
    J Urol. 2020;204:649-660.
    PubMed     Abstract available


    September 2020
  63. CHANG SS
    Re: Bacillus Calmette-Guerin (BCG) Therapy Lowers the Incidence of Alzheimer's Disease in Bladder Cancer Patients.
    J Urol. 2020 Sep 21:101097JU000000000000128202.
    PubMed    


  64. CHANG SS
    Re: Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer within a Large, Diverse Integrated Delivery System.
    J Urol. 2020 Sep 21:101097JU000000000000128201.
    PubMed    


  65. ATALA A
    Re: A Genetically Defined Disease Model Reveals That Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 Sep 21:101097JU000000000000128501.
    PubMed    


  66. REGMI SK, Kalapara A, Konety BR
    The Need for Interim Assessment of Neoadjuvant Chemotherapy Response for Muscle Invasive Bladder Cancer: Can We Help Prevent Definitive Treatment Delay in Non-responders?
    J Urol. 2020 Sep 18:101097JU0000000000001381. doi: 10.1097/JU.0000000000001381.
    PubMed    


  67. LAVIANA AA, Stone BV, Avulova S
    Editorial Comment.
    J Urol. 2020;204:458-459.
    PubMed    


  68. KRETSCHMER A
    Editorial Comment.
    J Urol. 2020;204:458.
    PubMed    


  69. CHANG SS
    Editorial Comment.
    J Urol. 2020;204:449.
    PubMed    


  70. CADEDDU JA
    Re: Long-Term Oncological Outcomes from an Early Phase Randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    J Urol. 2020;204:598.
    PubMed    


  71. DASON S, Cha EK, Falavolti C, Vertosick EA, et al
    Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations.
    J Urol. 2020;204:460-465.
    PubMed     Abstract available


    August 2020
  72. ORESTA B, Braga D, Lazzeri M, Frego N, et al
    The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.
    J Urol. 2020 Aug 28:101097JU0000000000001336. doi: 10.1097/JU.0000000000001336.
    PubMed     Abstract available


  73. CHANG SS
    Re: Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    J Urol. 2020 Aug 21:101097JU0000000000001260. doi: 10.1097/JU.0000000000001260.
    PubMed    


  74. CHANG SS
    Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Aug 21:101097JU000000000000126001.
    PubMed    


  75. CHANG SS
    Re: Cigarette Smoking is Associated with Adverse Pathological Response and Increased Disease Recurrence amongst Patients with Muscle-Invasive Bladder Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Cystectomy: A Single-Centre
    J Urol. 2020 Aug 21:101097JU000000000000126002.
    PubMed    


  76. HAJIRAN A, Azizi M, Aydin AM, Zemp L, et al
    Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy.
    J Urol. 2020 Aug 12:101097JU0000000000001325. doi: 10.1097/JU.0000000000001325.
    PubMed     Abstract available


  77. LIM A, Gregg JR
    Editorial Comment.
    J Urol. 2020;204:245-246.
    PubMed    


  78. CHENG L
    Editorial Comment.
    J Urol. 2020;204:246.
    PubMed    


  79. DE JONG JJ, Liu Y, Boorjian SA, Bivalacqua TJ, et al
    A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
    J Urol. 2020;204:239-246.
    PubMed     Abstract available


  80. KIM DK, Kim JW, Ro JY, Lee HS, et al
    Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.
    J Urol. 2020;204:215-223.
    PubMed     Abstract available


  81. CHANG SS
    Re: Smoking Cessation: A Report of the Surgeon General.
    J Urol. 2020;204:384.
    PubMed    


  82. DASON S, Wong NC, Donahue TF, Meier A, et al
    Utility of Routine Preoperative (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.
    J Urol. 2020;204:254-259.
    PubMed     Abstract available


  83. DECASTRO GJ, Sui W, Pak JS, Lee SM, et al
    A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guerin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    J Urol. 2020;204:247-253.
    PubMed     Abstract available


    July 2020
  84. OSTERMAN CK, Deal AM, McCloskey H, Nyrop KA, et al
    Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU0000000000001323. doi: 10.1097/JU.0000000000001323.
    PubMed     Abstract available


  85. CHANG SS
    Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU000000000000121902.
    PubMed    


  86. ATALA A
    Re: The CUL4B-miR-372/373-PIK3CA-AKT Axis Regulates Metastasis in Bladder Cancer.
    J Urol. 2020 Jul 27:101097JU000000000000122201.
    PubMed    


  87. TAN WS, Kelly JD
    Editorial Comment.
    J Urol. 2020;204:56-57.
    PubMed     Abstract available


  88. SHKOLYAR E, Mach KE, Liao JC
    Editorial Comment.
    J Urol. 2020;204:56.
    PubMed    


  89. MORI K, Mostafaei H, Enikeev DV, Lysenko I, et al
    Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:58-62.
    PubMed     Abstract available


  90. VAN KESSEL KEM, de Jong JJ, Ziel-van der Made ACJ, Roshani H, et al
    A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    J Urol. 2020;204:50-57.
    PubMed     Abstract available


  91. CHANG SS
    Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy.
    J Urol. 2020;204:184.
    PubMed    


    June 2020
  92. CHANG SS
    Re: National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.
    J Urol. 2020 Jun 30:101097JU0000000000001175. doi: 10.1097/JU.0000000000001175.
    PubMed    


  93. CHANG SS
    Re: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jun 30:101097JU000000000000117501.
    PubMed    


  94. ATALA A
    Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer Progression.
    J Urol. 2020 Jun 18:101097JU000000000000117901.
    PubMed    


  95. CHANG SS
    Re: The Impact of Non-Urothelial Variant Histology on Oncological Outcomes following Radical Cystectomy.
    J Urol. 2020;203:1060.
    PubMed    


  96. SZYMANSKI KM, Misseri R, Whittam B, Hollowell N, et al
    Additional Surgeries after Bladder Augmentation in Patients with Spina Bifida in the 21st Century.
    J Urol. 2020;203:1207-1213.
    PubMed     Abstract available


  97. FOERSTER B, Abufaraj M, Petros F, Azizi M, et al
    Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    J Urol. 2020;203:1101-1108.
    PubMed     Abstract available


    May 2020
  98. GRIEBLING TL
    Re: Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries with Bladder Cancer: A SEER-Medicare Analysis.
    J Urol. 2020 May 13:101097JU000000000000110204.
    PubMed    


  99. CHANG SS
    Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory.
    J Urol. 2020 May 12:101097JU000000000000111402.
    PubMed     Abstract available


  100. ATALA A
    Re: A Genetically Defined Disease Model Reveals that Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 May 12:101097JU0000000000001117. doi: 10.1097/JU.0000000000001117.
    PubMed    


  101. CHANG SS
    Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions.
    J Urol. 2020 May 12:101097JU000000000000111401.
    PubMed    


  102. CHANG SS
    Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases.
    J Urol. 2020;203:880.
    PubMed    


  103. WITJES JA
    Editorial Comment.
    J Urol. 2020;203:908-909.
    PubMed    


    April 2020
  104. ROUPRET M, Gontero P, McCracken SRC, Dudderidge T, et al
    Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Non Muscle Invasive Bladder Cancer Follow up: A Blinded, Prospective Cohort, Multicentric European Study.
    J Urol. 2020 Apr 21:101097JU0000000000001084. doi: 10.1097/JU.0000000000001084.
    PubMed     Abstract available


  105. ATALA A
    Re: Hypermethylation of FOXA1 and Allelic Loss of PTEN Drive Squamous Differentiation and Promote Heterogeneity in Bladder Cancer.
    J Urol. 2020 Apr 9:101097JU0000000000001058. doi: 10.1097/JU.0000000000001058.
    PubMed    


  106. CHANG SS
    Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    J Urol. 2020 Apr 9:101097JU0000000000001055. doi: 10.1097/JU.0000000000001055.
    PubMed    


  107. BECERRA MF, Venkatramani V, Reis IM, Soodana-Prakash N, et al
    Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.
    J Urol. 2020 Apr 9:101097JU0000000000001029. doi: 10.1097/JU.0000000000001029.
    PubMed     Abstract available


  108. CHANG SS
    Re: Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery after Surgery Protocol.
    J Urol. 2020;203:660.
    PubMed    


    March 2020
  109. SHARMA V, Wymer KM, Borah BJ, Saigal CS, et al
    Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2020 Mar 19:101097JU0000000000001023. doi: 10.1097/JU.0000000000001023.
    PubMed     Abstract available


  110. CHANG SS
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2020 Mar 17:101097JU000000000000099902.
    PubMed    


  111. NABAVIZADEH R, Joshi SS
    Editorial Comment.
    J Urol. 2020;203:511.
    PubMed    


  112. MONTORSI F, Moschini M, Gallina A, Briganti A, et al
    Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2020;203:624.
    PubMed    


  113. MULLER G, Butea-Bocu M, Brock O, Hanske J, et al
    Association between Development of Metabolic Acidosis and Improvement of Urinary Continence after Ileal Neobladder Creation.
    J Urol. 2020;203:585-590.
    PubMed     Abstract available


  114. ZHANG JH, Ericson KJ, Thomas LJ, Knorr J, et al
    Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach.
    J Urol. 2020;203:512-521.
    PubMed     Abstract available


  115. VENKATRAMANI V, Reis IM, Castle EP, Gonzalgo ML, et al
    Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.
    J Urol. 2020;203:522-529.
    PubMed     Abstract available


    February 2020
  116. INABA H, Kimura T, Onuma H, Sato S, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Feb 18:101097JU0000000000000804. doi: 10.1097/JU.0000000000000804.
    PubMed     Abstract available


  117. ATALA A
    Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAs.
    J Urol. 2020 Feb 12:101097JU0000000000000781. doi: 10.1097/JU.0000000000000781.
    PubMed    


  118. ATALA A
    Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression.
    J Urol. 2020 Feb 12:101097JU000000000000078101.
    PubMed    


  119. WEINER AB, Kundu SD
    Editorial Comment.
    J Urol. 2020;203:290-291.
    PubMed    


  120. CHANG SS
    Re: Effectiveness of Adjuvant Chemotherapy after Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-Invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    J Urol. 2020;203:250.
    PubMed    


    January 2020
  121. GARNIER S, Vendrell J, Boillot B, Karsenty G, et al
    Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis.
    J Urol. 2020 Jan 20:101097JU0000000000000752. doi: 10.1097/JU.0000000000000752.
    PubMed     Abstract available


  122. ATALA A
    Re: Epigenetic Loss of AOX1 Expression via EZH2 Leads to Metabolic Deregulations and Promotes Bladder Cancer Progression.
    J Urol. 2020 Jan 13:101097JU000000000000073202.
    PubMed    


  123. CHANG SS
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU0000000000000729. doi: 10.1097/JU.0000000000000729.
    PubMed    


  124. CHANG SS
    Re: Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000072902.
    PubMed    


  125. SIEGEL C
    Re: Delayed (18)F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer.
    J Urol. 2020 Jan 7:101097JU0000000000000718. doi: 10.1097/JU.0000000000000718.
    PubMed    


  126. GRIEBLING TL
    Re: Frailty as a Predictor of Complications after Radical Cystectomy: A Prospective Study of Various Preoperative Assessments.
    J Urol. 2020;203:9.
    PubMed    


  127. ALDHAAM NA, Elsayed AS, Jing Z, Richstone L, et al
    Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC.
    J Urol. 2020;203:57-61.
    PubMed     Abstract available


  128. CHECK DK, Leo MC, Banegas MP, Bulkley JE, et al
    Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy.
    J Urol. 2020;203:159-163.
    PubMed     Abstract available


    December 2019
  129. STEINBERG RL, Thomas LJ, Brooks N, Mott SL, et al
    Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.
    J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688.
    PubMed     Abstract available


  130. CHANG SS
    Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-G
    J Urol. 2019 Dec 3:101097JU0000000000000676. doi: 10.1097/JU.0000000000000676.
    PubMed    


  131. WEIN AJ
    Re: Long-Term Follow-Up after Cystectomy for Bladder Pain Syndrome: Pain Status, Sexual Function and Quality of Life.
    J Urol. 2019;202:1101-1102.
    PubMed    


  132. LENIS AT
    Editorial Comment.
    J Urol. 2019;202:1134-1135.
    PubMed    


  133. ALBERSHEIM J, Sathianathen NJ, Zabell J, Renier J, et al
    Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition after Radical Cystectomy.
    J Urol. 2019;202:1143-1149.
    PubMed     Abstract available


  134. SIGHINOLFI MC, Rocco B, Micali S, Bianchi G, et al
    Re: Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;202:1271-1272.
    PubMed    


  135. RASKOLNIKOV D, Brown B, Holt SK, Ball AL, et al
    Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis.
    J Urol. 2019;202:1136-1142.
    PubMed     Abstract available


  136. AL HUSSEIN AL AWAMLH B, Shoag JE, Ravikumar V, Posada L, et al
    Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
    J Urol. 2019;202:1248-1254.
    PubMed     Abstract available


    November 2019
  137. SCHAEFFER EM
    Re: Reduced Recurrence of Low-Grade Papillary Bladder Tumors Associated with Asymptomatic Bacteriuria.
    J Urol. 2019;202:849.
    PubMed    


  138. ATALA A
    Re: Recurrent Activating Mutations of PPARgamma Associated with Luminal Bladder Tumors.
    J Urol. 2019;202:869.
    PubMed    


  139. PEYTON CC, Reich RR, Tang D, Alford B, et al
    Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review.
    J Urol. 2019;202:913-919.
    PubMed     Abstract available


  140. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2019;202:927-935.
    PubMed     Abstract available


  141. MCALPINE K, Lavallee LT, Stacey D, Moodley P, et al
    Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.
    J Urol. 2019;202:1001-1007.
    PubMed     Abstract available


    October 2019
  142. LOTAN Y
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 25:101097JU0000000000000625. doi: 10.1097/JU.0000000000000625.
    PubMed    


  143. MONTORSI F, Moschini M, Briganti A
    Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guerin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 Oct 24:101097JU0000000000000624. doi: 10.1097/JU.0000000000000624.
    PubMed    


  144. CHANG SS
    Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence.
    J Urol. 2019 Oct 16:101097JU0000000000000599. doi: 10.1097/JU.0000000000000599.
    PubMed    


  145. RITCH CR, Velasquez MC, Kwon D, Becerra MF, et al
    Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort.
    J Urol. 2019 Oct 14:101097JU0000000000000593. doi: 10.1097/JU.0000000000000593.
    PubMed     Abstract available


  146. LABBATE C, Werntz RP, Adamic B, Steinberg GD, et al
    The Impact of Omission of Intraoperative Frozen Section Prior to Orthotopic Neobladder Reconstruction.
    J Urol. 2019;202:763-769.
    PubMed     Abstract available


  147. SINGLA N
    Editorial Comment.
    J Urol. 2019;202:688.
    PubMed    


  148. SEFIK E, Bozkurt IH, Basmaci I, Celik S, et al
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819.
    PubMed    


  149. LUO Y, Wang X, Xiao Y
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819-820.
    PubMed    


    September 2019
  150. LIEM EI, Oddens JR, Vernooij R, Li R, et al
    The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guerin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Da
    J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566.
    PubMed     Abstract available


  151. GRIEBLING TL
    Re: The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients with Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-Matched Study.
    J Urol. 2019 Sep 18:101097JU0000000000000559. doi: 10.1097/JU.0000000000000559.
    PubMed    


  152. GRIEBLING TL
    Re: Disparities in Bladder Cancer Treatment and Survival amongst Elderly Patients with a Pre-Existing Mental Illness.
    J Urol. 2019 Sep 18:10109701JU00005857524193298.
    PubMed    


  153. CHANG SS
    Re: Prognostic Significance of Lymphatic, Vascular and Perineural Invasion for Bladder Cancer Patients Treated by Radical Cystectomy.
    J Urol. 2019 Sep 18:10109701JU0000585772800505.
    PubMed    


  154. GRIEBLING TL
    Re: High-Precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-Day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
    J Urol. 2019 Sep 18:10109701JU00005857643430962.
    PubMed    


  155. GRIEBLING TL
    Re: Cost-Effectiveness of Surveillance Schedules in Older Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU00005857564955687.
    PubMed    


  156. GRIEBLING TL
    Re: Evaluation of Cause of Death after Radical Cystectomy for Patients with Bladder Cancer: The Impact of Age at the Time of Surgery.
    J Urol. 2019 Sep 18:10109701JU000058576026685.
    PubMed    


  157. CHANG SS
    Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU000058576872427.
    PubMed    


  158. MOREY AF
    Re: Dual Prosthetic Implantation after Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    J Urol. 2019 Sep 13:101097JU0000000000000549. doi: 10.1097/JU.0000000000000549.
    PubMed    


  159. ATALA A
    Re: Bladder Cancer Extracellular Vesicles Drive Tumorigenesis by Inducing the Unfolded Protein Response in Endoplasmic Reticulum of Nonmalignant Cells.
    J Urol. 2019 Sep 12:10109701JU00005851520364998.
    PubMed    


  160. LAGUNA MP
    Re: Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2019;202:456-457.
    PubMed    


  161. KHANNA A, Saarela O, Lawson K, Finelli A, et al
    Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes.
    J Urol. 2019;202:490-497.
    PubMed     Abstract available


    August 2019
  162. BJURLIN MA, Nielsen ME
    Editorial Comment.
    J Urol. 2019;202:246.
    PubMed    


  163. RICHARD PO, Bashir S, Riverin BD, Alibhai SMH, et al
    Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study.
    J Urol. 2019;202:319-325.
    PubMed     Abstract available


    July 2019
  164. CHANG SS
    Re: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
    J Urol. 2019 Jul 31:10109701JU00005794560657170.
    PubMed    


  165. CHANG SS
    Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model.
    J Urol. 2019 Jul 31:101097JU0000000000000479. doi: 10.1097/JU.0000000000000479.
    PubMed    


  166. CHANG SS
    Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    J Urol. 2019 Jul 31:10109701JU00005794608369953.
    PubMed    


  167. ATALA A
    Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research.
    J Urol. 2019 Jul 9:10109701JU000057698421354.
    PubMed    


  168. CHANG SS
    Re: Population-Based Assessment of Racial/Ethnic Differences in Utilization of Radical Cystectomy for Patients Diagnosed with Bladder Cancer.
    J Urol. 2019 Jul 9:10109701JU0000576988055492.
    PubMed    


  169. FILIPPOU P, Smith AB
    Editorial Comment.
    J Urol. 2019;202:89.
    PubMed    


    June 2019
  170. KUROIWA K, Inokuchi J, Nishiyama H, Kojima T, et al
    Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    J Urol. 2019 Jun 28:101097JU0000000000000422. doi: 10.1097/JU.0000000000000422.
    PubMed     Abstract available


  171. RAVVAZ K, Weissert JA, Downs TM
    American Urological Association Non-muscle Invasive Bladder Cancer Risk Model Validation: Should patient age be added to the risk model?
    J Urol. 2019 Jun 12:101097JU0000000000000389. doi: 10.1097/JU.0000000000000389.
    PubMed     Abstract available


  172. CHANG SS
    Re: Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-A Prospective Double-Blind Clinical Study.
    J Urol. 2019 Jun 10:10109701JU00005691889046242.
    PubMed    


  173. CHANG SS
    Re: Disseminated Mycobacterium bovis Infection Post-Kidney Transplant following Remote Intravesical BCG Therapy for Bladder Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000381. doi: 10.1097/JU.0000000000000381.
    PubMed    


  174. WEI L, Hussein AA, Ma Y, Azabdaftari G, et al
    Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;201:1105-1114.
    PubMed     Abstract available


    May 2019
  175. WESTERGREN DO, Gardmark T, Lindhagen L, Chau A, et al
    A Nationwide Population Based Analysis of Organ-Confined Muscle-Invasive Bladder Cancer Patients Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014.
    J Urol. 2019 May 30:101097JU0000000000000350. doi: 10.1097/JU.0000000000000350.
    PubMed     Abstract available


  176. LOTAN Y, Inman BA, Davis LG, Kassouf W, et al
    Evaluation of the UroVysion Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    J Urol. 2019 May 23:101097JU0000000000000355. doi: 10.1097/JU.0000000000000355.
    PubMed     Abstract available


  177. MORERA DS, Lahorewala SS, Belew D, Ghosh S, et al
    Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA.
    J Urol. 2019 May 21:101097JU0000000000000351. doi: 10.1097/JU.0000000000000351.
    PubMed     Abstract available


  178. CHANG SS
    Re: Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004-2013).
    J Urol. 2019 May 8:10109701JU000055962335906.
    PubMed    


  179. CHANG SS
    Re: Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.
    J Urol. 2019 May 8:10109701JU00005596222828385.
    PubMed    


  180. CHANG SS
    Re: Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    J Urol. 2019 May 8:101097JU0000000000000332. doi: 10.1097/JU.0000000000000332.
    PubMed    


  181. MENG MV, Gschwend JE, Shore N, Grossfeld GD, et al
    Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.
    J Urol. 2019 May 1:101097JU0000000000000297. doi: 10.1097/JU.0000000000000297.
    PubMed     Abstract available


  182. WOLDU SL
    Editorial Comment.
    J Urol. 2019;201:901.
    PubMed    


  183. METCALF M, Glazyrine V, Glavin K, Dahlgren A, et al
    The Feasibility of a Health Care Application in the Treatment of Patients Undergoing Radical Cystectomy.
    J Urol. 2019;201:902-908.
    PubMed     Abstract available


  184. ROTH B, Furrer MA, Giannakis I, Vartolomei MD, et al
    Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.
    J Urol. 2019;201:909-915.
    PubMed     Abstract available


    April 2019
  185. ABUFARAJ M, Tabung FK, Shariat SF, Moschini M, et al
    Association between inflammatory potential of diet and bladder cancer risk:Results from three US prospective cohort studies.
    J Urol. 2019 Apr 22:101097JU0000000000000279. doi: 10.1097/JU.0000000000000279.
    PubMed     Abstract available


    March 2019
  186. CHANG SS
    Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy.
    J Urol. 2019 Mar 29:10109701JU0000557728168538.
    PubMed    


  187. CHANG SS
    Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer.
    J Urol. 2019 Mar 29:101097JU0000000000000252. doi: 10.1097/JU.0000000000000252.
    PubMed    


  188. CHANG SS
    Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Mar 29:10109701JU000055772739723.
    PubMed    


  189. CHANG SS
    Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU000055464194059.
    PubMed    


  190. CHANG SS
    Re: Partial Bladder Boost Using Lipiodol Marking during Image-Guided Radiotherapy for Bladder Cancer.
    J Urol. 2019 Mar 13:101097JU0000000000000218. doi: 10.1097/JU.0000000000000218.
    PubMed    


  191. GRIEBLING TL
    Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    J Urol. 2019 Mar 13:10109701JU00005546361960937.
    PubMed    


  192. GRIEBLING TL
    Re: Outcomes of Radiosensitisation in Elderly Patients with Advanced Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU00005546347386712.
    PubMed    


  193. GRIEBLING TL
    Re: Real-World Effectiveness of Chemotherapy in Elderly Patients with Metastatic Bladder Cancer in the United States.
    J Urol. 2019 Mar 13:10109701JU0000554635814908.
    PubMed    


  194. WINTERS BR, Wen L, Holt SK, Dash A, et al
    Does the diagnosis of bladder cancer lead to higher rates of smoking cessation? Findings from the Medicare Health Outcomes Survey.
    J Urol. 2019 Mar 5:101097JU0000000000000206. doi: 10.1097/JU.0000000000000206.
    PubMed     Abstract available


  195. LEO MC, Gilbert SM, Wendel CS, Krouse RS, et al
    Development of a goal elicitation measure to support bladder cancer patients' choice about urinary diversion.
    J Urol. 2019 Mar 5:101097JU0000000000000203. doi: 10.1097/JU.0000000000000203.
    PubMed     Abstract available


  196. CHANG SS
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
    J Urol. 2019;201:442.
    PubMed    


  197. CHANG SS
    Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer.
    J Urol. 2019;201:441-442.
    PubMed    


  198. CHANG SS
    Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer.
    J Urol. 2019;201:441.
    PubMed    


  199. PARKER DC, Abboud MA, Patel SG
    Is Routine Removal of the Ovaries Advisable during Radical Cystectomy?
    J Urol. 2019;201:455-456.
    PubMed    


    February 2019
  200. CHANG SS
    Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: .
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000166.
    PubMed    


  201. CHANG SS
    Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554054.35801.
    PubMed    


  202. CHANG SS
    Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554055.35801.
    PubMed    


  203. GRIEBLING TL
    Re: Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000162.
    PubMed    


  204. GRIEBLING TL
    Re: Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553996.66966.
    PubMed    


  205. GRIEBLING TL
    Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553995.59343.
    PubMed    


  206. ATALA A
    Re: Identification of MicroR-106b as a Prognostic Biomarker of p53-Like Bladder Cancers by ActMiR.
    J Urol. 2019;201:231.
    PubMed    


  207. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: .
    J Urol. 2019;201:225-226.
    PubMed    


  208. WANG DS
    Re: A Prospective Randomized Pilot Study Evaluating an ERAS Protocol versus a Standard Protocol for Patients Treated with Radical Cystectomy and Urinary Diversion for Bladder Cancer.
    J Urol. 2019 Feb 1. doi: 10.1097/JU.0000000000000154.
    PubMed    


    January 2019
  209. EBRAHIMI H, Amini E, Pishgar F, Moghaddam SS, et al
    Global, Regional, and National Burden of Bladder Cancer, 1990 - 2016: Results from the Global Burden of Disease Study 2016.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000025.
    PubMed     Abstract available


  210. CHANG SS
    Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000097.
    PubMed    


  211. CHANG SS
    Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553308.83315.
    PubMed    


  212. ATALA A
    Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment.
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553307.75692.
    PubMed    


  213. CHANG SS
    Re: Pathologic Response in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Is Therapeutic Effect Owing to Chemotherapy or TURBT?
    J Urol. 2019;201:30.
    PubMed    


  214. CHANG SS
    Re: Adjuvant Sandwich Chemotherapy plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: A Randomized Phase 2 Trial.
    J Urol. 2019;201:29.
    PubMed    


  215. KIMURA S, Mari A, Foerster B, Abufaraj M, et al
    Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:46-53.
    PubMed     Abstract available


    December 2018
  216. XUE W, Yang L, Wei Q
    Re: Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: R. S. Liao, M. Gupta, Z. R. Schwen, H. D. Patel, M. Kates, M. H. Johnson, N. M. Hahn, D. McConkey, T. J.
    J Urol. 2018;200:1378-1379.
    PubMed    


    November 2018
  217. ATALA A
    Re: An FGFR3/MYC Positive Feedback Loop Provides New Opportunities for Targeted Therapies in Bladder Cancers.
    J Urol. 2018;200:947-948.
    PubMed    


  218. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.
    J Urol. 2018;200:942-943.
    PubMed    


  219. GRIEBLING TL
    Re: Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    J Urol. 2018;200:922.
    PubMed    


    October 2018
  220. PEYTON CC, Henriksen C, Reich RR, Azizi M, et al
    Estimating Minimally Important Differences for the Bladder Cancer Index Using Distribution- and Anchor-Based Approaches.
    J Urol. 2018 Oct 17. pii: S0022-5347(18)43986-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  221. FRANSEN VAN DE PUTTE EE, Pos F, Doodeman B, van Rhijn BWG, et al
    Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43985-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  222. CHANG SS
    Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:696-697.
    PubMed    


    September 2018
  223. CHANG SS
    Re: Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:497.
    PubMed    


  224. CHANG SS
    Re: Association between Number of Endoscopic Resections and Utilization of bacillus Calmette-Guerin Therapy for Patients with High-Grade, Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:496-497.
    PubMed    


  225. WHITSON JM
    Editorial Comment.
    J Urol. 2018;200:539-540.
    PubMed    


    August 2018
  226. FEUERSTEIN MA
    Editorial Comment.
    J Urol. 2018;200:290.
    PubMed    


  227. PATEL S, Cookson MS
    Editorial Comment.
    J Urol. 2018;200:290-291.
    PubMed    


  228. ZARGAR-SHOSHTARI K, Sexton WJ
    Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.
    J Urol. 2018;200:457-458.
    PubMed    


  229. HAMILTON-REEVES JM, Stanley A, Bechtel MD, Yankee TM, et al
    Perioperative Immunonutrition Modulates Inflammatory Response after Radical Cystectomy: Results of a Pilot Randomized Controlled Clinical Trial.
    J Urol. 2018;200:292-301.
    PubMed     Abstract available


    July 2018
  230. HAIFLER M
    Editorial Comment.
    J Urol. 2018;200:59-60.
    PubMed    


  231. FILSON CP
    Editorial Comment.
    J Urol. 2018;200:59.
    PubMed    


  232. MEEKS JJ, Glaser AP
    Editorial Comment.
    J Urol. 2018;200:60.
    PubMed    


    June 2018
  233. DOWNS TM, Weissert JA, Ravvaz K
    Can we improve non-muscle-invasive bladder cancer (NMIBC) guideline adherence with smarter risk-stratification?
    J Urol. 2018 Jun 12. pii: S0022-5347(18)43357-5. doi: 10.1016/j.juro.2018.
    PubMed    


  234. AUDENET F, Waingankar N, Ferket BS, Niglio SA, et al
    Effectiveness of transurethral resection (TUR) plus systemic chemotherapy as definitive treatment for muscle-invasive bladder cancer (MIBC) in population-level data.
    J Urol. 2018 Jun 4. pii: S0022-5347(18)43313-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


    May 2018
  235. MAZZA P, Moran GW, Li G, Robins DJ, et al
    Conservative Management Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
    J Urol. 2018 May 19. pii: S0022-5347(18)43234-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  236. MAKELA VJ, Kotsar A, Tammela TL, Murtola TJ, et al
    Bladder cancer survival in men using 5-alpha-reductase inhibitors.
    J Urol. 2018 May 3. pii: S0022-5347(18)43085-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  237. ATALA A
    Re: Evasion of Immunosurveillance by Genomic Alterations of PPARgamma/RXRalpha in Bladder Cancer.
    J Urol. 2018;199:1115-1116.
    PubMed    


  238. CHANG SS
    Re: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    J Urol. 2018;199:1111-1112.
    PubMed    


  239. CHANG SS
    Re: Intravesical rAd-IFNalpha/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Urol. 2018;199:1110-1111.
    PubMed    


    April 2018
  240. CHANG SS
    Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Urol. 2018;199:891-892.
    PubMed    


  241. CHANG SS
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    J Urol. 2018;199:891-892.
    PubMed    


    March 2018
  242. KAPADIA AA, Acevedo AM, Liu JJ, Garzotto M, et al
    Unconventional Bladder Preservation: Factors predicting Failure to Receive Definitive Surgery following Chemotherapy for Non-metastatic Muscle Invasive Bladder Cancer within the National Cancer Database.
    J Urol. 2018 Mar 15. pii: S0022-5347(18)42581-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  243. PERLIS N, Krahn MD, Boehme KE, Alibhai SM, et al
    The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
    J Urol. 2018 Mar 9. pii: S0022-5347(18)42498-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


    February 2018
  244. UHLIG A, Amir Hosseini AS, Simon J, Lotz J, et al
    Gender-specific differences in disease-free, cancer-specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39380-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  245. CHANG SS
    Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer.
    J Urol. 2018;199:341-342.
    PubMed    


  246. CHANG SS
    Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guerin.
    J Urol. 2018;199:340-342.
    PubMed    


    January 2018
  247. ZARGAR H, Shah JB, van Rhijn BW, Daneshmand S, et al
    Neoadjuvant dose dense MVAC versus GC in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy.
    J Urol. 2018 Jan 9. pii: S0022-5347(18)30036-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  248. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer.
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30006-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  249. CHANG SS
    Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guerin: Results from European Organ
    J Urol. 2018;199:26.
    PubMed    


  250. CHANG SS
    Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances.
    J Urol. 2018;199:25-26.
    PubMed    


    December 2017
  251. CHANG SS
    Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Urol. 2017;198:1208.
    PubMed    


  252. DANESHMAND S, Patel S, Lotan Y, Pohar K, et al
    Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (Hal) in the Surveillance of Bladder Cancer: A Phase Iii, Comparative, Multi-Center Study.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    November 2017
  253. CASILLA-LENNON MM, Choi SK, Deal AM, Bensen JT, et al
    Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life.
    J Urol. 2017 Nov 16. pii: S0022-5347(17)77917-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  254. KOUMPAN Y, Jaeger M, Mizubuti GB, Tanzola R, et al
    Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Non-Muscle Invasive Bladder Cancer.
    J Urol. 2017 Nov 14. pii: S0022-5347(17)77909-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  255. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.
    PubMed    


  256. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.
    PubMed    


  257. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.
    PubMed    


  258. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.
    PubMed    


  259. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.
    PubMed    


    October 2017
  260. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  261. RYAN S, Serrell EC, Karabon P, Mills G, et al
    The Association Between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77715-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    September 2017
  262. CHANG SS
    Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation.
    J Urol. 2017;198:482-483.
    PubMed    


  263. CHANG SS
    Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    J Urol. 2017;198:482-483.
    PubMed    


  264. SANCHEZ A, Wszolek MF, Niemierko A, Clayman RH, et al
    Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77426-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    August 2017
  265. NARAYAN VM, Adejoro O, Schwartz I, Ziegelmann M, et al
    The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77411-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  266. SMITH ZL, Johnson SC, Golan S, McGinnis JR, et al
    Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort.
    J Urol. 2017 Aug 28. pii: S0022-5347(17)77409-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  267. HURLE R, Lazzeri M, Vanni E, Lughezzani G, et al
    Active surveillance for low-risk Non-Muscle Invasive Bladder Cancer (NMIBC): a confirmatory and resource consumption study from Bladder cancer Italian Active Surveillance (BIAS) project.
    J Urol. 2017 Aug 25. pii: S0022-5347(17)77391-0. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  268. ATALA A
    Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo.
    J Urol. 2017;198:258-259.
    PubMed    


  269. CHANG SS
    Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    J Urol. 2017;198:255.
    PubMed    


    July 2017
  270. CHANG SS
    Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    J Urol. 2017;198:40.
    PubMed    


  271. CHANG SS
    Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    J Urol. 2017;198:39-41.
    PubMed    


    June 2017
  272. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  273. LAGUNA MP
    Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel.
    J Urol. 2017;197:1437-1438.
    PubMed    


    April 2017
  274. CHANG SS, Bochner BH, Chou R, Dreicer R, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
    J Urol. 2017 Apr 26. pii: S0022-5347(17)57836-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  275. RAVVAZ K, Walz ME, Weissert JA, Downs TM, et al
    Predicting non-muscle invasive bladder cancer recurrence and progression in a US population.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54785-0. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    March 2017
  276. KIM JH, Chung BI
    Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5alpha-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and
    J Urol. 2017 Mar 29. pii: S0022-5347(17)30226-4. doi: 10.1016/j.juro.2017.
    PubMed    


  277. BOEHM BE, Cornell JE, Wang H, Mukherjee N, et al
    Efficacy of Bacillus Calmette-guerin Strains for the Treatment of non-muscle Invasive Bladder Cancer: a Systematic Review and Network Meta-analysis.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39246-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  278. TOBERT CM, Hamilton-Reeves JM, Norian LA, Hung C, et al
    The Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications on Cystectomy for Bladder Cancer.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39247-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  279. CHANG SS
    Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer.
    J Urol. 2017;197.
    PubMed    


    February 2017
  280. STEINBERG GD
    Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Gr
    J Urol. 2017 Feb 6. pii: S0022-5347(16)32070-5. doi: 10.1016/j.juro.2016.
    PubMed    


    January 2017
  281. CHANG SS
    Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;197:52-54.
    PubMed    


  282. CHANG SS
    Re: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    J Urol. 2017;197:53-54.
    PubMed    


    December 2016
  283. BEUKERS W, van der Keur KA, Kandimalla R, Vergouwe Y, et al
    FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.
    J Urol. 2016 Dec 31. pii: S0022-5347(16)32099-7. doi: 10.1016/j.juro.2016.
    PubMed     Abstract available


  284. SHENOY SP, Marla PK, Sharma P, Batchu CK, et al
    Re: Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T
    J Urol. 2016 Dec 28. pii: S0022-5347(16)31927-9. doi: 10.1016/j.juro.2016.
    PubMed    


  285. CHOU R, Selph S, Buckley DI, Fu R, et al
    Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2016 Dec 24. pii: S0022-5347(16)32091-2. doi: 10.1016/j.juro.2016.
    PubMed     Abstract available


    October 2016
  286. CHOU R, Selph S, Buckley DI, Fu R, et al
    Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis.
    J Urol. 2016 Oct 22. pii: S0022-5347(16)31585-3. doi: 10.1016/j.juro.2016.
    PubMed     Abstract available


  287. ATALA A
    Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness.
    J Urol. 2016;196:1314.
    PubMed    


  288. CHANG SS
    Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer.
    J Urol. 2016;196:1045.
    PubMed    


  289. CHANG SS
    Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study.
    J Urol. 2016;196:1045-6.
    PubMed    


  290. CHANG SS
    Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study.
    J Urol. 2016;196:1044-6.
    PubMed    


    May 2016
  291. WANG DS
    Re: Long-Term Changes in Renal Function Outcomes following Radical Cystectomy and Urinary Diversion.
    J Urol. 2016;195:1511.
    PubMed    


  292. MOREY AF
    Re: Outcomes of the Endoscopic Treatment of Bladder Neck Contractures in the Orthotopic Neobladder.
    J Urol. 2016;195:1508-9.
    PubMed    


  293. CHANG SS
    Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience.
    J Urol. 2016;195:1381-2.
    PubMed    


  294. VENKATRAMANI V, Parekh DJ
    Editorial Comment.
    J Urol. 2016;195:1375.
    PubMed    


  295. KRISHNAN N, Liu X, Lavieri MS, Hu M, et al
    A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.
    J Urol. 2016;195:1362-7.
    PubMed     Abstract available


  296. HUSSEIN AA, Hashmi Z, Dibaj S, Altartir T, et al
    Reoperations following Robot-Assisted Radical Cystectomy: A Decade of Experience.
    J Urol. 2016;195:1368-76.
    PubMed     Abstract available


    April 2016
  297. PATEL S, Cookson MS
    Radical Cystectomy-The Waiting is the Hardest Part...or is it?
    J Urol. 2016;195.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: